UBS BIO-TECH （HK） CO., LIMITED

ROCKVILLE, Md., Sept. 6, 2022 /PRNewswire/ -- REGENXBIO Inc. ( Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference Date: Wednesday, September 14, 2022 Fireside chat: 2:55 p.m. ET Location: Sheraton Hotel, New York, NY UBS Biotech South Beach Conference 2022 Date: September 29, 2022 Location: Mondrian South Beach, Miami, FL A live webcast of the Morgan Stanley 20th Annual Global Healthcare Conference fireside chat can be accessed in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation. About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025. Contacts: Dana Cormack Corporate Communications [email protected] Investors: Chris Brinzey, ICR Westwicke 339-970-2843 [email protected] SOURCE REGENXBIO Inc.

ROCKVILLE, Md., Sept. 6, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference Date: Wednesday, September 14, 2022 Fireside chat: 2:55 p.m. ET Location: Sheraton Hotel, New York, NY UBS Biotech South Beach Conference 2022 Date: September 29, 2022 Location: Mondrian South Beach, Miami, FL A live webcast of the Morgan Stanley 20th Annual Global Healthcare Conference fireside chat can be accessed in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation. About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025. Contacts: Dana Cormack Corporate Communications dcormack@regenxbio.com Investors: Chris Brinzey, ICR Westwicke 339-970-2843 chris.brinzey@westwicke.com View original content to download multimedia: SOURCE REGENXBIO Inc. Company Codes: NASDAQ-NMS:RGNX